TARS: Wutah bathi EPS kuartalan Tarsus Pharmaceuticals, Inc.

The reliability of Tarsus Pharmaceuticals (TARS) is based on the management of regulatory risks and a focused portfolio of ophthalmological products. The quarterly EPS growth rate on GURU.Markets reflects the precise execution of the strategy, where the value is maintained at -4796.30. High patent barriers protect developments, while the rapid market penetration of the blepharitis drug confirms the colossal demand for innovative therapy.

Tarsus Pharmaceuticals Inc (TARS) - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan saka 04.07.2022 nganti 15.11.2026

Ringkesan rincian data analitis tarsusrx.com (TARS)

- rega saham lan prakiraan rega para ahli:

Rega saham Tarsus Pharmaceuticals, Inc.|TARS - Bagan tingkat prakiraan

- informasi kapitalisasi pasar:

Kapitalisasi pasar Tarsus Pharma|TARS - Total Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham Tarsus Pharmaceuticals|TARS - Aset Bersih Perusahaan|Rasio Kapitalisasi marang Aset Bersih tarsusrx.com|TARS - Aset Agregat Bisnis

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal Tarsus Pharmaceuticals|TARS - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Tarsus Corp|TARS - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Tarsus Pharmaceuticals Inc|TARS - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Tarsus Pharmaceuticals|Indikator likuiditas cepet tarsusrx.com

- indikator bathi lan kelipatan valuasi:

TARS - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Tarsus Pharmaceuticals|TARS - Pangali P/E|Rega marang bathi mangsa ngarep Tarsus Pharmaceuticals|TARS - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Tarsus Pharmaceuticals Inc|TARS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Tarsus Pharmaceuticals|TARS - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan tarsusrx.com|TARS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Tarsus Pharmaceuticals

- data pendapatan lan penerimaan dodolan:

TARS - Pendapatan dodolan perusahaan|Prakiraan pendapatan perusahaan Tarsus Pharmaceuticals, Inc.|TARS - Rasio rega marang dodolan|Multiplikator Forward P/S Tarsus Pharmaceuticals, Inc.

Analisis komprehensif perusahaan:Tarsus Pharmaceuticals

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year. This metric measures the efficiency of generating net income available to shareholders after all operating expenses. For Tarsus Pharmaceuticals (TARS), this rate reflects the commercial success of sales for its ophthalmologic drug against blepharitis. Analyzing the quarterly EPS change allows for the identification of a systemic slowdown in profitability. Stable growth on this chart confirms the quality of capital management.

Pesaing wigati